New Compuware Strobe Takes Proactive Performance Problem

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
New Compuware Strobe Takes Proactive Performance Problem Resolution to Advanced Level

Solution Innovations and Deeper Integration With PurePath Technology ® Break Down IT Silos,
Reduce Application Backlogs and Accelerate Time-to-market

DETROIT, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Compuware Corporation (Nasdaq: CPWR ), the technology performance company, today announced deep enhancements to Compuware Strobe , a key component of Compuware APM for Mainframe . Strobe is the leading mainframe application performance measurement and analysis solution that has helped customers pinpoint application inefficiencies for more than four decades. Throughout that time Compuware has continuously innovated Strobe, most recently enriching it with greater automation, intelligent analytics and increasing ease of use to help those less familiar with mainframe applications to diagnose problems more quickly and effectively.

"We are excited about Strobe's new functionality, particularly the iStrobe and DB2 reporting enhancements," said Mariusz Dąbek, Team Leader, PKO Bank Polski. "Our staff will be able to pinpoint the root cause of an application problem faster and more easily with iStrobe's sorting and filtering capabilities. We also anticipate saving on CPU usage because of Strobe's ability to generate an SQL analysis report on demand without first having to take a Strobe measurement. Additionally, more comprehensive DB2 reporting means we'll get access to the critical data we need so we can solve application issues more quickly."

As Strobe customers around the globe manage the performance of increasingly complex applications that span multiple platforms, they will benefit from the solution's many enhancements, including:

-- An enhanced user interface in iStrobe. This new interface utilizes advanced Web technologies to provide an easier navigation path to the root cause. Charts and graphs visually summarize key performance information and provide alternate paths to navigation.

  • An enhanced status display. Users can now view the status of all measurements and profiles in one display. They can also sort, filter and tag the data to improve productivity.
  • A graphical user interface for taking measurements. This interface allows inexperienced or new users to submit measurement requests using a familiar graphical user interface, without having to learn ISPF.

-- Improved DB2 reporting. Users can request an SQL analysis report on demand, without having to take a Strobe measurement. DB2 reports will now indicate the maximum CPU and elapsed times for local SQL statements, as well as the DB2 buffer pool hit ratio. Along with existing iStrobe DB2 reports, having this critical information available in one report makes it easier for DBAs to resolve performance issues quickly.

-- Enhanced Strobe Advisor. Strobe Advisor automatically highlights the largest performance opportunities and provides recommendations on how to resolve problems. Strobe Advisor now includes information on CICS, IMS and Language Environment (LE) performance issues.

-- Increased visibility into business transactions . Strobe furthers its integration with PurePath for z/OS CICS and now includes the ability to profile CICS transactions from within the dynaTrace dashboard. This facility provides more detailed information on specific transactions of interest.

-- Enhanced SMF Record collection. Strobe is now collecting SMF 30 jobstep interval records, in addition to the SMF 70 and SMF 30 jobstep termination records. The interval records allow customers to see which jobsteps are executing when the system is running at its peak capacity. Tuning or rescheduling these jobs will have a direct effect on the MIPS consumed on an LPAR. Customers concerned about their rolling four-hour average will find this data of great importance.

Strobe also supports newly announced capabilities that help IT break down the barriers between development, QA and operations. Deeper integration with Compuware's other Developer Productivity solutions now enable the automated capture of detailed information about an application problem--including Strobe measurements and deep-dive analysis--which helps development teams jumpstart the resolution process. For a description of the capabilities, read the detailed announcement .

"The new enhancements to Strobe coupled with deeper integration with our developer productivity solutions help our customers address the ongoing concerns of a transitioning workforce, increased application complexity, mainframe workloads and the ever-present threat of application outages," said Kris Manery, Senior Vice President and General Manager, Compuware Mainframe Solutions. "As mobile and other technologies increase the complexity of the mainframe application environment, new and inexperienced staff will need the expertise built into Strobe to help them quickly and easily identify performance issues and their root causes."

About the Compuware Mainframe Solutions

Compuware's Mainframe solutions help the world's leading organizations maximize developer productivity, minimize costs and deliver better service. The Solutions are available within the Compuware Workbench , an open development environment that features an intuitive and easy-to-use graphical user interface. Workbench makes common mainframe tasks faster and simpler to perform for both experienced mainframers as well as those new to the mainframe, enabling companies to develop new services faster, more efficiently and with higher quality utilizing existing resources.

About Compuware APM for Mainframe

Compuware APM for Mainframe is the industry's first and only 24/7 end-to-end performance monitoring solution that traces every transaction from the browser through distributed tiers and deep into the mainframe. Compuware APM for Mainframe unites PurePath for z/OS with Compuware Strobe to provide an exclusive level of visibility into mainframe applications that includes CICS and Java transaction performance with deep root-cause analysis. With unparalleled visibility across the enterprise, organizations can view the impact distributed code has on mainframe workload, enabling them to reduce MIPS and postpone upgrades, speed mean time to resolution and improve customer satisfaction. For more information, visit www.compuware.com/apm4mainframe .

Follow us on:

Compuware Corporation

Compuware is the technology performance company, and we exist solely to help our customers optimize the performance of their most important and innovative technologies—those that drive their businesses forward. Today, more than 7,100 companies, including many of the world's largest organizations, depend on Compuware and our new-generation approach to performance management to do just that . Learn more at www.compuware.com .

Press Contact Mary McCarthy, Public Relations Manager, Compuware - Mainframe Solutions , (313) 227-8188 For Sales and Marketing Information Compuware Corporation One Campus Martius Detroit, MI 48226 800-521-9353 http://www.compuware.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 397

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 149

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 205

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 606

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 288

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 196

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 245

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 223

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 322

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading

Top 5 Most Recently Viewed Articles

Care Synergy and RCC Medical Equipment Launch New Partnership

Updated Category News Views 320

Care Synergy and RCC Medical Equipment Form Joint Venture In an exciting development for healthcare services, Care Synergy and RCC Medical Equipment Co. have announced their plans to create a strategic joint venture aimed at improving healthcare delivery in the Colorado Front Range region. This partnership will leverage the strengths of both organizations to provide...

Continue Reading
Revitalizing China's Tourism with High-Tech Cultural Experiences

Updated Category News Views 217

Revitalizing China's Tourism Through High-Tech Cultural Experiences China's tourism industry is undergoing an exciting transformation, fueled by the innovative use of advanced technology paired with its rich cultural heritage. A remarkable example is in Chongqing Municipality, where the city's skyline has become a vibrant showcase of cultural stories, highlighted by...

Continue Reading
Intriguing Insights into United States Steel Options Trades

Updated Category News Views 111

Analyzing Unusual Options Activity in United States Steel Recently, there's been notable market activity where investors with deep pockets are taking a more bearish stance on United States Steel (X). This trend is definitely something for retail traders to pay attention to, especially when navigating the complexities of the stock market. Today's options history unveiled...

Continue Reading
Mesoblast's Operational Highlights and Financial Insights Unveiled

Updated Category News Views 185

Mesoblast Limited's Webcast for Financial Results On a recent occasion, Mesoblast Limited (NASDAQ: MESO; ASX: MSB), a pioneer in allogeneic cellular medicine for inflammatory diseases, announced a webcast to delve into their operational achievements and financial metrics for the half year concluding December 31, 2024. Details of the Webcast Event The engaging webcast is...

Continue Reading
Investors of DXC Technology Prepare for Class Action Lawsuit

Updated Category News Views 77

Investors of DXC Technology Company Take Action In recent months, investors who purchased common stock from DXC Technology Company (NYSE: DXC) have been given a significant opportunity to participate in a class action lawsuit. This situation arises from allegations of securities fraud that are said to have affected many individuals who bought shares during specific key...

Continue Reading